Table 1.
Hazard ratio for clinical variables for progression‐free survival and overall survival
| Clinical variable | Progression‐free survival | Overall survival | ||
|---|---|---|---|---|
| Hazard ratio | p value | Hazard ratio | p value | |
| Lactate dehydrogenase | 1.166 | <.0001 | 1.230 | <.0001 |
| Absolute lymphocyte count/absolute neutrophil count ratio | 0.679 | .0006 | 0.799 | .0383 |
| Presence of visceral metastasis | 0.548 | .0059 | N/A | |
| Presence of lung metastasis | N/A | 1.768 | .0081 | |
| More than 10 tumors | 2.239 | .0031 | 1.297 | .3875 |
| Presence of 4–9 tumors | 1.426 | .1947 | 0.682 | .22 |
| Prior therapy received | 1.275 | .1823 | 1.228 | .2895 |
| Dual BRAF/MEK therapy | 0.614 | .0144 | 0.662 | .0494 |
| Sequential BRAF, MEK therapy | 0.500 | .0492 | 0.939 | .8512 |
| Presence of V600E mutation | 0.288 | <.0001 | 0.593 | .0506 |
| M‐stage IVb | 0.329 | .0092 | 0.961 | .9306 |
| M‐stage IVc | 0.577 | .1105 | 1.537 | .2195 |
| M‐stage IVd | 0.538 | .1381 | 1.434 | .4165 |
N/A, not applicable; variable was not selected on backward selection process as a potentially significant variable for inclusion in the final model.